Dementia care Update 2013/10/21. F/81 with Alzheimer s Disease
|
|
- Norah Fisher
- 6 years ago
- Views:
Transcription
1 Dementia care Update Stanley KF Tam Executive council member, Coordinator of Education & Publication Subcommittee, Hong Kong Alzheimer s Disease Association Honorary Clinical Assistant Professor, Faculty of MED, HKU Associate Consultant, Depart of MED, QEH / HKBH F/81 with Alzheimer s Disease referred to memory clinic, from private neurologist for impaired memory good past health, cataract with extraction c/o : Progressive memory lost over 3 years initially affect short term memory, gradually deteriorating recent few months, have problems in operating home electrical appliance deranged cooking technique change of personality very argumentative, very defensive, and protective sometimes very emotional MMSE 18/30: education up to secondary school level Orientation 6/10 Registration 3/3 Attention & calculation 1/5 Recall 1/3 Language 7/8 Praxia 0/1 Physical exam: Unremarkable including neurological exam Unremarkable blood test: CBP L / RFT, Ca PO4 Thyroid function VDRL Vitamin B12, Folate 1
2 Dementia An acquired syndrome of decline in memory and other cognitive functions > 55 illnesses can cause dementia Common causes of Dementia in HK 1. Alzheimer s Disease ( 阿爾茲海默氏症 ) 73.5 % 2. Vascular dementia 22.4 % 3. Others 4.1% Prevalence of dementia in the Hong Kong community a population survey in 2005/06 : Elderly Health Services, Department of Health and Department of Psychiatry, Chinese University of Hong Kong; The number of people with dementia worldwide is currently estimated at 35.6 million. This number will double by 2030 and more than triple by
3 Epidemiology of dementia in HK Epidemiology of dementia in HK In 2006, research findings from DH and CUHK showed that, about 1 in 10 community-dwelling population aged 70 or above had dementia, and 1 in 3 aged 85 or above had dementia Prevalence of dementia in the Hong Kong community a population survey in 2005/06 : Elderly Health Services, Department of Health and Department of Psychiatry, Chinese University of Hong Kong; Epidemiology of dementia in HK Assuming no increase in prevalence rates, the number of people aged 60+ with dementia will still increase from 0.11 million (2010) to 0.28 million (2036) 患者的數目 ( 萬 ) Number (Ten thousands) ( 資料來源 : 賽馬會流金頌計劃研究系列 : 老年癡呆症 ) Alzheimer s disease Multiple cognitive deficits manifested by memory impairment and one or more of apraxia, agnosia, aphasia or disturbance in executive functioning (ability to initiate, plan and execute daily tasks). Multiple cognitive deficits manifested by memory impairment and one or more of aphasia, apraxia, agnosia or disturbance in executive functioning (ability to initiate, plan and execute daily tasks). Significant impairment in social or occupational functioning Gradual onset and continuing cognitive decline Symptoms not due to neurologic, systemic or substance abuse conditions known to cause dementia 3
4 Neurocognitive Disorder (DSM-V) 1 The DSM-IV diagnoses of dementia is under the newly named entity major neurocognitive disorder (NCD). 2 The term dementia is not precluded from use. 3 Furthermore, a less severe level of cognitive impairment, mild NCD, which is a new disorder that permits the diagnosis of less disabling syndromes that may nonetheless be the focus of concern and treatment. Major Neurocognitive Disorder 1 Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition) based on: Concern of the individual, a knowledgeable informant, or the clinician that there has been a significant decline in cognitive function; and A substantial impairment in cognitive performance, preferably documented by standardized neuropsychological testing or, in its absence, another quantified clinical assessment. Major Neurocognitive Disorder Mild Neurocognitive Disorder The cognitive deficits interfere with independence in everyday activities (i.e., at a minimum, requiring assistance with complex instrumental activities of daily living such as paying bills or managing medications). The cognitive deficits do not occur exclusively in the context of a delirium. The cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia). 1 The cognitive deficits do not interfere with capacity for independence in everyday activities (i.e., complex instrumental activities of daily living such as paying bills or managing medications are preserved, but greater effort, compensatory strategies, or accommodation may be required). start Exelon 1.5 mg bd Gradually stepped up to 4.5mg bd over 4 months Pharmacology treatment 4
5 Drugs for Alzheimer s Disease 1 Disease modifying agents 2 Symptomatic treatment 3 Treatment of neuropsychiatric symptoms (psychosis, depression) Kaj Blennow Lancet 2006 Cholinergic Hypothesis in AD Acetylcholine (ACh) is important for learning & memory ACh is deficient in the brains of persons with AD, esp. in moderate to severe disease stages Loss of cholinergic neurons Enhanced ACh concentrations may improve memory Drugs for Alzheimer s Disease Acetyl-cholinesterase inhibitors (AChEIs) 膽鹼酯酵素抑制劑 remain the mainstay of symptomatic treatment. Two independent meta-analyses have confirmed the efficacy of these drugs with mild-to-moderate Alzheimer s disease. Ritchie CW. Am J Geriatr Psychiatry 2004 Lanctot KL. CMAJ 2003 Donepezil (Aricept) Galantamine (Reminyl) Rivastigmine (Exelon) Patient with (a) mild to moderate Alzheimer s disease and MMSE 10 26, (b) Without medical contraindication / precaution with C.I. and (c) patient is compliant or there is reliable caregiver to ensure compliance. [Geri / Neur / Psy specialists] start Exelon 1.5 mg bd Gradually stepped up to 4.5mg bd over 4 months Associated with reduced appetite, weight loss from 108 lb 103 lb No other GI symptom, denied other drug intake, no overdose of Exelon system enquiry & exam, blood test, stool for occult blood : unremarkable OGD refused stepped down Exelon, no improvement 5
6 mood low side crying during interview GDS 12/15 Add Fluoxetine 10mg om, switch Exelon to Aricept 5mg N 2 months later...(fluoxetine 10mg om + Aricept 5mg N) Same low mood, poor appetite, BW 100lb Stopped Aricept, keep Fluoxetine 10mg om Counseling to daughter: daughter criticize the patients overtly Counseling to patient: son being unemployed encourage more daytime activities and outdoor activities, introduce HKADA Alzheimer s Disease Association 4 weeks later, mood better, stepped up Fluoxetine Re-start Exelon patch 4.6mg / D stepped up to 9.5mg /D in 1 month Well tolerated Appetite improved BW 110lb Clinical experience suggests that introducing cholinesterase inhibitors at low doses, increasing the dose gradually, and administering the medication with meals may limit gastrointestinal side effects. Watch out for organic cause other than drug side effect. Look for and treat depression. Behavioral and psychological symptoms are common in Alzheimer s disease Proper assessment and intervention can benefit patient and career Behavioral and pharmacological intervention are equally important. 6
7 Exelon Transdermal 9.5 mg/24 h Patch Neurology 69 (Suppl 1) July 24, 2007 Dose Titration Rivastigmine Patch: Smooth Continuous Delivery Through the Skin Treatment groups (double-dummy, double-blind): Rivastigmine once-daily patch 20 cm 2 and placebo capsules Rivastigmine once-daily patch 10 cm 2 and placebo capsules Rivastigmine twice-daily capsules 3 12 mg/day and placebo patch Placebo patch and capsules Doses were titrated at 4-weekly intervals Patch 5 20 cm 2 Patch 5 10 cm 2 Weeks 1 4 Weeks 5 8 Weeks 9 12 Weeks Patch 5 cm 2 Patch 10 cm 2 Patch 15 cm 2 Patch 20 cm 2 Patch 5 cm 2 Patch 10 cm 2 Rivastigmine (ng/ml) Rivastigmine 10 cm 2 patch Rivastigmine 6 mg bid capsule Time (h) Capsule 3 12 mg 3 mg/day 6 mg/day 9 mg/day 12 mg/day Placebo 10 cm 2 patch delivered average concentrations provided by an oral dose of 6 mg bid (12 mg per day), based on PK modeling Patients Receiving the Patch Demonstrated Improved Cognitive Functions Most Frequent Adverse Events Neurology 69 (Suppl 1) July 24, 2007 Neurology 69 (Suppl 1) July 24,
8 Rivastigmine Patch shows Good Skin Tolerability Caregiver Preference for Patch versus Capsule None/slight/mild Moderate/severe % patients Itching Redness Oedema Pain, stinging and/or burning % caregivers reporting a preference % Patch 28% Capsule Safety population C-ITT population Preference at 24 weeks (n = 985) p < , patch versus capsule new patients : Start 4.6 mg D for at least 4 weeks. If well tolerated, step up to 9.5 mg D. For patients already receiving Exelon capsules : taking < 6 mg day oral Exelon : switch to the 4.6 mg D patch for at least 4 weeks taking 6 mg day oral Exelon : may switch directly to target 9.5 mg D patch. In both instances, the first patch should be applied the day after the last oral dose. Apply to: Upper and lower back Upper arm Chest The skin should be clean, dry and hairless before the patch is applied Normal daily activities, such as bathing, are permitted Donepezil for dementia due to Alzheimer s disease The Cochrane Library 2009, Issue years after starting treatment BW 111 lb walk unaided, mood OK, social smile, intake good self care OK, take cared by daughter mostly home bound, outdoor need assistance less initiation, less speech ear wax+ MMSE 13/30 (Jun/06) - 18/30 (Mar/03) Fluoxetine 20mg N, 1 st AChEI (max dose), add memantine 5mg om, olive oil for ear wax Donepezil is beneficial for people with mild, moderate and severe dementia due to Alzheimer s disease, in being associated with improvements in cognitive function and activities of daily living. Adverse effects were consistent with the cholinergic actions of the drug. Effects on cognition remained measurable and statistically significant at 52 weeks of treatment in one study. 8
9 Action of NMDA receptors antagonist in AD Benefits of NMDA receptors antagonist across domains in moderate to severe AD Memantine N-methyl-D-aspartate receptor (NMDAR) antagonist A central mechanism in learning and memory is long-term potentiation (LTP) which is mediated by the neurotransmitter glutamate via the NMDA receptor However, in AD, glutamate receptors of the NMDA type are overactivated, with the resulting continuous mild activation leading to neuronal damage and impairment of learning. Winblad et al. Memantine in Moderate to Severe Alzheimer s disease: a Meta-Analysis of Randomised Clinical Trials, Dement Geriatr Cogn Disord 2007;24:20-27 Memantine in mod-severe AD already receiving Donepezil Memantine in mod-severe AD already receiving Donepezil Tariot PN. JAMA 2004 Tariot PN. JAMA 2004 Memantine adverse effect 9
10 4 weeks after starting memantine daughter report: more cheerful, more conversation, more alert at day time thus more participation in day time activities step up to full dose 10mg bd in 6 months Nov 2006 report aggressiveness: shouting loud if against her wish, rushed to bank to get money daughter: care-giver stress, low mood step back memantine to 15mg/D, agitation resolved patient moved to live with son + DIL Sep years after starting treatment come to clinic FU walk unaided with daughter MMSE 10/30 live with son + DIL, sometimes cared by daughter during weekend need supervision / assistance in ADL e.g. toileting, bathing repeated face cleansing, searching behaviour especially night time no delusion, hallucination observed Severe Dementia noncompetitive antagonist of glutamate N- methyl-d-aspartate (NMDA) receptors, effective and safe in patients with moderate to severe Alzheimer s disease Donepezil is approved by the US FDA. Non-pharmacology treatment 10
11 Summary Management of Alzheimer s disease Assessment We do not have a cure but we do have treatments Management of Dementia pharmacological non-pharmacological Target: Delay progression Manage symptoms (cognitive, behavioral, psychological) Maintain functioning 11
12 FU Jan 2011 BW 111 lb walk unaided, mood OK, social smile, intake good self care OK, take cared by DIL, outdoor need assistance Exelon patch 9.5mg/D, Fluoxetine 10mg N, memantine 15mg/D 12
Diagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationMedications for Alzheimer s disease: are they right for you?
Medications for Alzheimer s disease: are they right for you? There are no medications today that can cure Alzheimer s disease. But there are currently four medications approved by Health Canada which can
More informationDementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician
Dementia Aetiology, pathophysiology and the role of neuropsychological testing Dr Sheng Ling Low Geriatrician Topics to cover Why is dementia important What is dementia Differentiate between dementia,
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationDrug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle
Drug Update Treatments for Cognitive Impairment in the Older Adult William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Current Drug Treatments for Alzheimer s Disease Cholinesterase Inhibitors:
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationDementia Pharmacotherapy
Dementia Pharmacotherapy 1 early therapeutic interventions can maximize pharmacologic efficacy with these agents 2 Selecting a Medication Not enough evidence to recommend one agent over another based on
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationThe Basics of Alzheimer s Disease
2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU
More informationMichael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center
Michael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center Dementia an acquired syndrome consisting of a decline in memory and other cognitive functions Alzheimer s Disease Fronto temporal
More informationDSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602)
SUPPLEMENT 2 RELEVANT EXTRACTS FROM DSM-5 The following summarizes the neurocognitive disorders in DSM-5. For the complete DSM-5 see Diagnostic and Statistical Manualof Mental Disorders, 5th edn. 2013,
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationThe most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M.
Cholinesterase Inhibitors in the Treatment of Dementia Jay M. Ellis, DO Dementia associated with probable Alzheimer s disease (AD) is one of the most common types of dementia. Patients with AD often have
More informationThe Psychopharmacology of Alzheimer s Disease. Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school
The Psychopharmacology of Alzheimer s Disease Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school Overview of Alzheimer s Disease Alzheimer s is a progressive degenerative disease Prevalence
More informationCognitive disorders. Dr S. Mashaphu Department of Psychiatry
Cognitive disorders Dr S. Mashaphu Department of Psychiatry Delirium Syndrome characterised by: Disturbance of consciousness Impaired attention Change in cognition Develops over hours-days Fluctuates during
More informationSignificance A Busy Clinician's Guide to Seniors with Memory Loss
Significance A Busy Clinician's Guide to Seniors with Memory Loss Victoria Braund MD FACP CMD Division of Geriatrics. NorthShore University HealthSystem Alzheimer's disease is the sixth leading cause of
More informationAlzheimer's Disease. Dementia
Alzheimer's Disease Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s Disease
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationDementia Prepared by: Joanne Leung Psychiatry Resident, University of Toronto
Dementia Prepared by: Joanne Leung Psychiatry Resident, University of Toronto Dementias are acquired neurodegenerative disorders involving a syndrome of cognitive impairment accompanied with social and
More informationIan McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAlzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,
2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,
More informationDementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE
Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be
More informationNEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationKnown as both a thief and murderer,
&A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer
More informationDr Georgina Train Consultant Psychiatrist EMDASS service and Continuing Care.
Dr Georgina Train Consultant Psychiatrist EMDASS service and Continuing Care. Consultant Psychiatrist of both General adult and Old Age Psychiatry. Work with Memory Service and a Continuing Care ward.
More informationPrimary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia
Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationTechnology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.
More informationUnderstanding Dementia
Understanding Dementia Dr. Dallas Seitz MD FRCPC Assistant Professor, Department of Psychiatry, Queen s University, Kingston, Ontario, Canada What s Next Information about Dementia, Elder Care and Supports
More informationPractical approach to pharmacological treatment and nonpharmacological intervention of dementia
Title Practical approach to pharmacological treatment and nonpharmacological intervention of dementia Author(s) Tam, SKF; Lee, NYM; Wong, GHY Citation HKMA CME Bulletin, 2014, n. September, p. 9-13 Issued
More informationIf you have dementia, you may have some or all of the following symptoms.
About Dementia Dementia may be caused by a number of illnesses that affect the brain. Dementia typically leads to memory loss, inability to do everyday things, difficulty in communication, confusion, frustration,
More informationPROJECTION: Worlds dementia population is expected to triple by 2050
DEMENTIA C L I S K C O N S U LTA N T P H Y S I C I A N I N A C U T E M E D I C I N E A N D G E R I AT R I C M E D I C I N E, B A R N E T H O S P I TA L, R O YA L F R E E N H S F O U N D AT I O N T R U
More informationDr. W. Dalziel Professor, Geriatric Medicine Ottawa Hospital. November /20/ Safety: Falls/Cooking/Unsafe Behaviour. 2.
How To Decide if an Elderly Person Can Stay at Home: The Interval of Need Concept Dr. W. Dalziel Professor, Geriatric Medicine Ottawa Hospital November 2013 3 Factors 1. Safety: Falls/Cooking/Unsafe Behaviour
More informationOutlines! Current Issue in Management. of Dementia! Cholinesterase Inhibitors! Medications that soon to be used in. Papan Thaipisuttikul, M.D.
Current Issue in Management of Dementia! Papan Thaipisuttikul, M.D. Department of Psychiatry Ramathibodi Hospital! Outlines! Current medications use in dementia management in Thailand. Medications that
More informationDementia: Diagnosis and Treatment
Dementia: Diagnosis and Treatment Outline 1. Risk factors and definition of dementia 2. Types of Dementias 3. MMSE and testing 4. Treatment options Cognitive decline with aging Mild changes in memory and
More informationPharmacy Drug Class Review
April 16, 2010 Pharmacy Drug Class Review Disclaimer: Specific agents may have variations Dementia Review Focus on available treatments for Alzheimer s disease Authored By: Sarah Davis, Pharm.D Candidate
More informationAlzheimer dementia: Starting, stopping drug therapy
REVIEW LUKE D. KIM, MD, FACP, CMD Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Center for Geriatric Medicine, Medicine
More informationEARLY DEMENTIA. University of Hawaii Geriatric Medicine Department
EARLY DEMENTIA University of Hawaii Geriatric Medicine Department INTRODUCTION Dementia is very prevalent Screening and early diagnosis is important Evaluation Dementia Management DEMENTIA IS VERY PREVALENT
More informationCauses of Transient Incontinence. Geriatrics: Urinary Incontinence, Dementia, and Delirium. Classification of Established Incontinence
Causes of Transient Geriatrics: Urinary, Dementia, and Delirium Carla Zeilmann, PharmD, BCPS St. Louis College of Pharmacy Therapeutics 3 Fall 2003 D delirium I infection A atrophic urethritis and vaginitis
More informationCurrent Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London
Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationOverview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?
Neuropsychological assessment of older adults: what, when and why? Benjamin Mast, Ph.D. Associate Professor & Vice Chair, Psychological & Brain Sciences Associate Clinical Professor, Family & Geriatric
More informationAlzheimer s disease. The facts in brief
Alzheimer s disease Dementia is an umbrella term used to describe various conditions which damage brain cells and lead to a loss of brain function over time. Dementia causes a progressive decline in a
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationDementia. patient, or. individuals whose treatment regimes have been initiated and stabilized by the hospital-based dementia specialist.
DEMENTIA UNIT NO. 3 PHARMACOLOGICAL TREATMENT OF DEMENTIA Dr Lim Wee Shiong ABSTRACT Pharmacotherapy is a vital part of the multi-pronged strategy in dementia management. All dementia patients should be
More informationDementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP
Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia
More informationScreening Summary (SS2)
15Screening SummarySS217 Aug 06 Depression in Alzheimer s Disease Study - 2 DIADS-2 Screening Summary (SS2) Keyed: ( ) Purpose: Document findings about eligibility for DIADS-2 and about medical and social
More informationClinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)
Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following
More informationDr. Adeniyi Mofoluwake and Stacy Kramer
Dr. Adeniyi Mofoluwake and Stacy Kramer Definition of Alzheimer s Disease Alzheimer's disease is a neurological disorder in which insidious onset of the death of brain cells causes memory loss and cognitive
More informationThe Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia
Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationOLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.
Psychiatric disorders of the elderly OLD AGE PSYCHIATRY Dementia Depression Delusional disorder/late onset schizophrenia Delirium Dementia definition LOCALISATION OF CEREBRAL FUNCTION Impairment of multiple
More informationRecommendations For the Use of Donepezil
Recommendations For the Use of Donepezil The trial of donepezil in patients with mild to moderate dementia due to probable AD was one recommendation made by the Canadian Consensus Conference on Dementia.
More informationAlzheimer Disease Agents Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Alzheimer Disease Agents Drug Class Prior Authorization Protocol This policy has been developed through review
More informationDementia is not normal aging!
The Future of Alzheimer s Disease Treatment Adam L. Boxer, MD, PhD Director, Alzheimer s Disease Clinical Trials Program Memory and Aging Center Assistant Professor of Neurology University of California,
More informationUnderstanding Dementia
Dementia Handbook for Carers Essex Understanding Dementia What is dementia? 1 Summary of dementia symptoms 4 Medication and treatment 5 1 Dementia is the name for several conditions that lead to the progressive
More informationPharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms
More informationDementia and Alzheimer s disease
Since 1960 Medicine Korat โรงพยาบาลมหาราชนครราชส มา Dementia and Alzheimer s disease Concise Reviews PAWUT MEKAWICHAI MD DEPARTMENT of MEDICINE MAHARAT NAKHON RATCHASIMA HOSPITAL 1 Prevalence Increase
More informationRational Medication Use in Dementia
Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this
More informationDementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018
Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review
More informationOCVAP Physician Guidelines Pocket Guide
OCVAP Physician Guidelines Pocket Guide OCVA Clinical Path Overview D i s c l a i m e r EDUCATE PATIENTS These guidelines are intended to be informational only. These guidelines are not intended to be,
More informationMemory Loss, Dementia and Alzheimer's Disease: The Basics
Memory Loss, Dementia and Alzheimer's Disease: The Basics What is memory loss? What is age-related memory loss? Typical changes Typical age-related changes involve: Making a bad decision once in a while
More informationDementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.
Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:
More informationMedication Treatments for Dementia. Stephen Thielke
Medication Treatments for Dementia Stephen Thielke Treatment is a MORAL decision. Facts can help you determine HOW to accomplish something. Facts cannot tell you WHAT YOU WANT to accomplish. Dementia Meds
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationAlzheimer s disease Treatment options
Alzheimer s disease Treatment options Treatment options Recent research has greatly improved our knowledge of Alzheimer s disease. Treatments for the disease are now available that may help to alleviate
More informationSHARED CARE OF MCI/EARLY DEMENTIA
SHARED CARE OF MCI/EARLY DEMENTIA BY DR. OLUFEMI BANJO MD, DTM, DCP, DIPA&DS, DHM, M.Med.Sc, FRCP(C) GERIATRIC PSYCHIATRIST. ASSISTANT MEDICAL DIRECTOR, ADULT MENTAL HEALTH AND ADDICTION, GRAND RIVER HOSPITAL
More informationObjectives. Prevalence of AD by age. Diagnosing and Managing Dementia in Ambulatory Practice
Diagnosing and Managing Dementia in Ambulatory Practice 35 th Annual Nurse Practitioners of Oregon Education Conference Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Objectives Review
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More information10 Facts We All Need to Know About Dementia (MNCD) in Old Age
10 Facts We All Need to Know About Dementia (MNCD) in Old Age DUNCAN ROBERTSON FRCP (LOND & EDIN) FRCPC MEDICAL ADVISOR TO ADVANCING DEMENTIA DIAGNOSIS AND MANAGEMENT IN ALBERTA AND PRIMARY HEALTH CARE
More informationMedications for treating people with dementia: summary of evidence on cost-effectiveness
Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017
More informationDEMENTIA NEWSLETTER for PHYSICIANS
DEMENTIA NEWSLETTER for PHYSICIANS Vol. 6, No. 4 OTTAWA AND RENFREW COUNTY Winter 2008 In This Issue... Mild Cognitive Impairment Monitoring Patient Response to Cognitive Enhancers CDN Diagnostic Assessment
More informationDelirium. Approach. Symptom Update Masterclass:
Symptom Update Masterclass: Delirium Jason Boland Senior Clinical Lecturer and Honorary Consultant in Palliative Medicine Wolfson Centre for Palliative Care Research Hull York Medical School University
More informationCognitive Assessment 4/29/2015. Learning Objectives To be able to:
Supporting the Desire to Age in Place: Important Considerations for the Aging Population AGENDA 8:45 9:00 AM Geriatric Principles Robert L. Kane, MD *9:00 9:55 AM Cognitive Assessments Ed Ratner, MD 10:00
More informationDEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER
OVERCOMING THE CHALLENGES OF MANAGING CHRONIC DISEASES IN PERSONS WITH DEMENTIA DEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER LEARNING OBJECTIVES Be familiar with the diagnostic criteria for
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Memantine ER (Namenda XR), galantamine (Razadyne, Razadyne ER) Reference Number: CP.CPA.102 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationPharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
More informationCME Geriatric medicine
CME GERIATRIC MEDICINE Clinical Medicine 2011, Vol 11, No 1: 67 71 CME Geriatric medicine Edited by John Young, professor of elderly care medicine, Academic Unit of Elderly Care and Rehabilitation, Bradford
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More information10/17/2017. Causes of Dementia Alzheimer's Disease Vascular Dementia Diffuse Lewy Body Disease Alcoholic Dementia Fronto-Temporal Dementia Others
1 Dementia Dementia comes from the Latin word demens, meaning out of mind. It is the permanent loss of multiple intellectual functions. It is progressive deterioration of mental powers accompanied by changes
More informationCommon Forms of Dementia Handout Package
Common Forms of Dementia Handout Package Common Forms of Dementia 1 Learning Objectives As a result of working through this module, you should be better able to: 1. Describe clinical features of 4 major
More informationPharmacotherapeutic aspects of dementia care in Malta
Review Article Pharmacotherapeutic aspects of dementia care in Malta Charles Scerri, Stephen Abela, Anthea Innes Abstract Dementia is the most common neurodegenerative disorder of old age affecting one
More informationMild Cognitive Impairment
Mild Cognitive Impairment The Role of the Family Physicians McGill Refresher Course December 2018 Fadi Massoud MD FRCPC, Internist-Geriatrician Centre Hospitalier Charles LeMoyne & Institut Universitaire
More informationForgetfulness: Knowing When to Ask for Help
National Institute on Aging AgePage Forgetfulness: Knowing When to Ask for Help Maria has been a teacher for 35 years. Teaching fills her life and gives her a sense of accomplishment, but recently she
More informationMental Health Disorders Civil Commitment UNC School of Government
Mental Health Disorders 2017 Civil Commitment UNC School of Government Edward Poa, MD, FAPA Chief of Inpatient Services, The Menninger Clinic Associate Professor, Baylor College of Medicine NC statutes
More informationLTC Research Influencing Practice
LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts
More informationAlzheimer s disease dementia: a neuropsychological approach
Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 EXELON 13.3 mg/24 hours, transdermal patch B/30 sachets (CIP: 34009 268 908 1 0) Applicant: NOVARTIS
More information4/11/2017. The impact of Alzheimer s disease. Typical changes. The impact of Alzheimer s disease. Problematic changes. Problematic changes
The impact of Alzheimer s disease Ron Petersen, MD, PhD, is Director of the Mayo Alzheimer's Disease Research Center. 2 The impact of Alzheimer s disease Typical changes Typical age-related changes involve:
More informationExecutive Summary. The Royal Australasian College of Physicians July 2012 Page 1 of 5
PBAC Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimer s disease Submission by The Royal Australasian College of Physicians July 2012 The Royal Australasian College of Physicians
More informationManaging Patients with Dementia using a Collaborative and Strength-based Approach
Managing Patients with Dementia using a Collaborative and Strength-based Approach Therapy Network Seminars, Inc. Nicole Dawson, PT, PhD, GCS Learning Objectives The Participant will be able to: Identify
More informationWHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by
WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together Presented by Our agenda for today Understanding behavioral symptoms in people living with dementia Briefly review key strategies
More informationEvaluation and Treatment of Dementia
Evaluation and Treatment of Dementia Jeffrey M. Burns, MD Edward H. Hashinger Professor of Neurology Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science Unit Disclosures
More informationThe world is graying: Dementia is an alarming issue
Guest Editorial Paper Sapkota et.al. N Sapkota, Fellowship (Geriatric Psychiatry) Associate Professor and Head, Department of Psychiatry B.P. Koirala Institute of Health Sciences, Dharan, Nepal The world's
More information